KMD Bioscience Co., Ltd.
400-621-6806
2023-08-29 Hits(320)
Adoptive immune cell therapy has been effective in treating haematological cancers. However, some patients experience disease relapse, which may be attributed to insufficient persistence of T cells. In addition, adoptive therapy using chimeric antigen receptor (CAR) T cells is more limited in solid tumours owing to the infiltration barriers and immunosuppressive microenvironment of these tumours. To address these challenges, high-throughput screening of modified T cells is the most efficient way to identify variant.
If you want to leam more about the aricles. please visit：https://www.nature.com/articles/s41577-023-00908-3
FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：info@kmdbioscience.com
Hot Line： +1-315-239-3085
Technical Support：sales@kmdbiosci.com